Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k
Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Baird analyst Brian Skorney maintains $Alto Neuroscience(ANRO.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 39.5% and a
Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical Developments
Alto Neuroscience Price Target Maintained With a $29.00/Share by Wedbush
Alto Neuroscience Analyst Ratings
Wedbush Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $29
Wedbush analyst Laura Chico maintains $Alto Neuroscience(ANRO.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 47.6% and a
Analysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance Is Not a Moderator of Response to Standard-of-Care Antidepressants
Wedbush Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $29
Wedbush analyst Laura Chico initiates coverage on $Alto Neuroscience(ANRO.US)$ with a buy rating, and sets the target price at $29.According to TipRanks data, the analyst has a success rate of 48.0%
Alto Neuroscience to Participate in Upcoming Investor Conferences
Wedbush Initiates Alto Neuroscience at Outperform
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $33
Jefferies analyst Andrew Tsai maintains $Alto Neuroscience(ANRO.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a success rate of 56.6% and
Buy Rating Affirmed for Alto Neuroscience, Inc. on Strong Clinical Trials and Strategic Precision Neuroscience Approach
Alto Neuroscience GAAP EPS of -$0.60
Alto Neuroscience | 10-Q: Quarterly report
Alto Neuroscience Q2 EPS $(0.60) Beats $(0.63) Estimate
Alto Neuroscience 2Q Loss/Shr 60c >ANRO
Express News | Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Optimistic Buy Rating for Alto Neuroscience Backed by Strategic Clinical Trials and Promising Data
Institutional Investors of Alto Neuroscience, Inc. (NYSE:ANRO) Must Be Disappointed After Last Week's 26% Drop